| 1 | The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study | Pharmaceuticals | Yuichi Shinozaki, Miki Ito et al. | 3 |
| 2 | Hypoglycemic coma owing to sensor device dysfunction after an automatic smartphone operating system update | Therapeutic Advances in Endocrinology and Metabolism | Saori Hashiguchi, Yumi Takiyama et al. | 0 |
| 3 | Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study | Therapeutic Advances in Endocrinology and Metabolism | Yuki Oe, Hiroshi Nomoto et al. | 0 |
| 4 | Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease | Diabetes & Metabolism Journal | Hiroshi Nomoto, Yuki Yamauchi et al. | 5 |
| 5 | Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study) | Diabetes Obesity and Metabolism | Akihiro Takahashi, Hiroshi Nomoto et al. | 2 |
| 6 | Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas | Pituitary | Hiraku Kameda, Akinobu Nakamura et al. | 1 |
| 7 | Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study) | Diabetes Obesity and Metabolism | Hiroshi Nomoto, Hiroki Yokoyama et al. | 8 |
| 8 | Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study) | Diabetes Obesity and Metabolism | Yuka Takahashi, Hiroshi Nomoto et al. | 20 |
| 9 | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study | Pharmaceutics | Hiroshi Nomoto, Yuki Oe et al. | 3 |
| 10 | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis | Pharmaceutics | Hiroshi Nomoto, Yuka Takahashi et al. | 9 |
| 11 | Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study) | BMJ Open | Hiroshi Nomoto, Akinobu Nakamura et al. | 3 |
| 12 | Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study | Journal of Diabetes Research | Yuki Oe, Hiroshi Nomoto et al. | 5 |
| 13 | Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study | Journal of Diabetes Investigation | Hiraku Kameda, Hiroshi Nomoto et al. | 6 |
| 14 | Impact of low-starch high-fiber pasta on postprandial blood glucose | Nutrition Metabolism and Cardiovascular Diseases | Akinobu Nakamura, Hiroshi Nomoto et al. | 7 |
| 15 | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin | Journal of Diabetes Investigation | Aika Miya, Akinobu Nakamura et al. | 1 |
| 16 | Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia | Journal of Diabetes Investigation | Akinobu Nakamura, Hiroshi Nomoto et al. | 13 |
| 17 | Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes | Journal of Diabetes Investigation | Hiroshi Nomoto, Akinobu Nakamura et al. | 10 |
| 18 | IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function | Nature Communications | Chiara Montemurro, Hiroshi Nomoto et al. | 64 |
| 19 | Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial | Journal of Diabetes Investigation | Akinobu Nakamura, Kohei Yamamoto et al. | 29 |
| 20 | Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes | Journal of Diabetes Investigation | Kiyohiko Takahashi, Kyu Yong Cho et al. | 7 |